Rare Victory For Generic Drug Industry In Patent Ruling

Law360, New York (January 18, 2006, 12:00 AM EST) -- Pharmaceutical giant AstraZeneca has lost a key U.S. court ruling concerning two patents covering the heart drug Toprol-XL in the latest setback in the company’s struggle to sustain its pipeline of blockbuster medications.

The ruling clears the way for rival pharmaceutical company Andrx Corp.'s generic version of the drug.

According to the judgment filed in a U.S. District Court for the Eastern District of Missouri, the patents, which were due to expire in September 2007, are “invalid and unenforceable” because they constitute double-patenting.

Generic drug maker...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.